U.S., April 21 -- ClinicalTrials.gov registry received information related to the study (NCT07538635) titled 'CAR-T Combined With ASCT in the Treatment of Relapsed/Refractory Large B-cell Lymphoma With High-risk Factors.' on April 13.

Brief Summary: This is a prospective, single-arm, single-center, open-label clinical study, aiming to evaluate the efficacy and safety of CAR-T combined with ASCT in the treatment of relapsed/refractory large B-cell lymphoma with high-risk factors.

Study Start Date: April 08

Study Type: INTERVENTIONAL

Condition: High-risk R/R LBCL

Intervention: BIOLOGICAL: Axicabtagene Ciloleucel

R/R LBCL with high-risk factors sequentially undergo leukapheresis, stem cell collection, bridging therapy (if applicable, a...